According to a phase II clinical trial, the drug rilonacept, which inhibits the protein interleukin-1 (IL-1), substantially reduces acute gout flares that occur at the start of uric acid-reducing therapy and is noted to be generally well tolerated with…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the preven…
Results from a new pharmacokinetic (PK) study presented at the annual meeting of the American College of Rheumatology (ACR) provide new evidence-based guidance for healthcare providers on using colchicine for gout flare prophylaxis in the presence of r…
X-ray images known as CT scans can help confirm gout in patients who are suspected of having the painful condition but receive negative results from traditional tests, a Mayo Clinic study has found. The type of CT scan analyzed, dual-energy computed to…
According to a study in the August 17 issue of JAMA, patients with severe, chronic gout who took pegloticase for 6 months as an alternative to conventional gout treatment that some patients may not respond to, showed greater improvements of uric acid l…
Injections of pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in 2 out of 5 patients with chronic gout that is resistant to conventional therapies, researchers report in the August 17, 2011, issue of …
A new study shows the prevalence of gout in the U.S. has risen over the last twenty years and now affects 8.3 million (4%) Americans. Prevalence of increased uric acid levels (hyperuricemia) also rose, affecting 43.3 million (21%) adults in the U.S. Gr…
Eight million Americans, almost 6% of men and 2% of women have got the gout, a painful affliction in which uric acid crystals are deposited in the joints. In a self reported survey, the prevalence of gout continues to climb along with rates of related…
